title: Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets.
abstract: Reducing the risk of pathogen transmission to transfusion recipients is one of the great concerns in transfusion medicine. Important among the measures suggested to minimise pathogen transmission is pathogen reduction technology (PRT) systems. The present study examined the effects of Mirasol PRT system on MCS+ apheresis platelets in vitro quality measures during a seven-day storage period at 22°C. Statistical analysis indicated no significant difference in platelet concentrations between the control and treated platelet concentrates (PCs) during the storage period. Glucose and lactate levels were measured to determine metabolic activities of control and treated platelets. In both control and treated platelets, the amount of glucose consumed and lactate produced increased significantly with storage time, but glucose consumption and lactate production rates were significantly higher in treated platelets compared with control platelets. The mean pH of treated PCs was decreased at all time points relative to control PCs but remained within acceptable limits. The expression of P-selectin was also higher in Mirasol PRT treated platelets throughout the storage period, but differences were not statistically significant on Days 1 and 4. Finally, visual inspection of swirling indicated that Mirasol PRT treatment of platelets is associated with platelet shape change. Overall, our results show that MCS+ apheresis platelets treated with Mirasol PRT can preserve adequate in vitro properties for at least 5 days of storage.
authors.affiliation: Department of Immunology and Transfusion Medicine, Akershus University Hospital, University of Oslo, Norway.
authors.forename: Maria Adele
authors.initials: MA
authors.lastname: Mastroianni
authors.forename: Abid Hussain
authors.initials: AH
authors.lastname: Llohn
authors.forename: Çiğdem Akalın
authors.initials: ÇA
authors.lastname: Akkök
authors.forename: Ruby
authors.initials: R
authors.lastname: Skogheim
authors.forename: Elna Rathe
authors.initials: ER
authors.lastname: Ødegaard
authors.forename: Monica Jenssen
authors.initials: MJ
authors.lastname: Nybruket
authors.forename: Annika
authors.initials: A
authors.lastname: Flesland
authors.forename: Seyed Ali
authors.initials: SA
authors.lastname: Mousavi
mesh_terms: D001792:Blood Platelets / Q000166:cytology* / Q000378:metabolism; D001793:Blood Preservation / Q000295:instrumentation / Q000379:methods*; D058731:Blood Safety / Q000295:instrumentation / Q000379:methods*; D004203:Disinfection / Q000295:instrumentation / Q000379:methods*; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000378:metabolism; D008297:Male; D010983:Plateletpheresis
chemical_list: D019344:Lactic Acid; D005947:Glucose
keywords: In vitro platelet quality; MCS+ apheresis platelets; Mirasol pathogen reduction technology